Production (Stage)
Akero Therapeutics, Inc.
AKRO
$46.36
-$2.61-5.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 29.58% | -7.80% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.66% | -4.50% | |||
| Operating Income | -3.66% | 4.50% | |||
| Income Before Tax | -1.00% | 3.69% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1.00% | 3.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.00% | 3.69% | |||
| EBIT | -3.66% | 4.50% | |||
| EBITDA | -3.68% | 4.52% | |||
| EPS Basic | 9.37% | 5.23% | |||
| Normalized Basic EPS | -5.92% | 18.92% | |||
| EPS Diluted | 9.37% | 5.23% | |||
| Normalized Diluted EPS | -5.92% | 18.92% | |||
| Average Basic Shares Outstanding | 11.45% | 1.63% | |||
| Average Diluted Shares Outstanding | 11.45% | 1.63% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||